Vir Biotechnology, Inc. (NASDAQ:VIR) Financings

Vir Biotechnology, Inc.

Financings

RaiseDate
Public offering of common stock
Announced: US$150M · US$10 a share · Leerink Partners +3
Dealers: Leerink Partners (co-lead), Morgan Stanley (co-lead), Evercore ISI (co-lead), Raymond James
Nov 13, 2026
Strategic investment of equity
Announced: US$25M
Buyers: Gilead ($25 million equity investment at a 30% premium)
Oct 14, 2026
Strategic investment of shares
Closed: US$75M raised · US$10.36 a share
Buyers: Astellas ($75 million equity investment at a price of $10.36 per share)
Apr 16, 2026
Public offering of common stock
Terms changed: US$150M · US$8.5 a share · Goldman Sachs & Co. LLC +3
Dealers: Goldman Sachs & Co. LLC (co-lead), Leerink Partners (co-lead), Evercore ISI (co-lead), Barclays (co-lead)
Feb 26, 2026

Read by 6ix AI from the company's releases